| Vasculitis and related conditions | Lifetime | 73 | NL 7 | 98.94 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 918 | NL 35 | 98.59 |
| Systemic Lupus Erythematosus Research | Lifetime | 429 | NL 26 | 98.66 |
| Celiac Disease Research and Management | Lifetime | 225 | NL 8 | 96.71 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 837 | NL 29 | 96.84 |
| Renal Diseases and Glomerulopathies | Lifetime | 672 | NL 26 | 97.10 |
| Vitamin D Research Studies | Lifetime | 495 | NL 13 | 96.73 |
| Inflammasome and immune disorders | Lifetime | 487 | NL 22 | 95.66 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 613 | NL 31 | 95.75 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 362 | NL 16 | 95.38 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 828 | NL 40 | 95.29 |
| Systemic Sclerosis and Related Diseases | Lifetime | 817 | NL 22 | 94.94 |
| Whipple's Disease and Interleukins | Lifetime | 59 | NL 2 | 93.70 |
| Multiple Sclerosis Research Studies | Lifetime | 997 | NL 33 | 94.70 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 854 | NL 39 | 94.07 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 581 | NL 15 | 93.06 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 937 | NL 39 | 85.68 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 791 | NL 23 | 82.14 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 244 | NL 9 | 96.50 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 451 | NL 21 | 93.40 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 281 | NL 11 | 93.49 |
| T-cell and B-cell Immunology | 2021-2025 | 461 | NL 15 | 90.21 |
| Celiac Disease Research and Management | 2021-2025 | 100 | NL 5 | 91.36 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 290 | NL 9 | 92.23 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 162 | NL 5 | 91.85 |
| Vasculitis and related conditions | 2021-2025 | 372 | NL 20 | 88.46 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 769 | NL 34 | 74.76 |
| Autoimmune Neurological Disorders and Treatments | 2021-2025 | 642 | NL 17 | 65.43 |